{
  "ticker": "CI",
  "content": "**Report Generated:** January 15, 2026  \n**Next Refresh:** April 16, 2026\n\n**Disclaimer:** This sell-side report was generated using Claude Sonnet 4 (claude-sonnet-4-20250514). Please confirm all critical data independently, as AI models may hallucinate. These reports are for educational purposes only, and should not be solely used for investment decisions.\n\n---\n\n# The Cigna Group (CI) - Comprehensive Analysis Report\n\n## 1. Company Overview\n\nThe Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.\n\nThe company operates through two primary segments: Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans; and health care coverage in its international markets.\n\nThe Cigna Group maintains sales capabilities in more than 30 countries and jurisdictions, and has approximately 165 million customer relationships around the world. As of late 2024, total customer relationships at December 31, 2024 increased 11% from December 31, 2023 to 182.2 million. Total pharmacy customers at December 31, 2024 increased 20% from December 31, 2023 to 118.3 million due to new sales and the continued expansion of relationships.\n\n## 2. Current Market Data\n\n**Stock Price**: As of Jan 15, 2026, Cigna (CI) is trading at a price of 271.00\n\n**Market Cap**: With a market cap of 75.2B, Cigna(CI) trades at $281.53.\n\n**52-Week Range**: The stock has fluctuated within a day range of 270.96 to 276.67, while its 52-week range spans from 239.51 to 350.00.\n\n**Analyst Price Targets**: The average 12-month price target for Cigna is USD326.91957, with a high estimate of USD378 and a low estimate of USD270. 21 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. On January 6, Bernstein raised the firm's price target on Cigna to $307 from $294 and kept a Market Perform rating on the shares. A day before this rating, Truist increased its price target for Cigna to $320 from $310, while maintaining a Buy rating on the shares.\n\n**Financial Metrics**: The stock has a price-to-earnings ratio of 12.31 and currently yields dividends of 2.2%.\n\n## 3. Existing Products/Services\n\n### Evernorth Health Services\n- **Pharmacy Benefits**: Evernorth, which includes pharmacy benefit services such as Express Scripts\n- **Specialty Pharmacy**: Including Accredo and specialty drug distribution\n- **Care Management**: Comprehensive care delivery and management solutions\n- **Biosimilar Programs**: Cordani also highlighted the company's efforts to offer their interchangeable Humira (adalimumab) biosimilar at no cost to patients. He added that the biosimilar use for eligible Humira prescriptions reached nearly 50% by the end of 2024, and the company plans to offer the same benefit for the Stelara (ustekinumab) biosimilar.\n\n### Cigna Healthcare\n- Medical insurance plans for commercial, government, and individual markets\n- Behavioral health, dental, and supplemental products\n- Medicare plans (divested to HCSC in March 2025)\n- International health insurance coverage\n\n### Key Programs\n- **EncircleRx**: A key factor in Evernorth's innovation is the data-driven EncircleRx program, which expanded to cover about 8 million lives in 2024. The program helps plan sponsors reduce costs and improve outcomes, with its Cardiodiabesity solution offering predictability in managing obesity, diabetes, and cardiovascular disease.\n\n## 4. Planned Products/Services/Projects\n\n### Revolutionary Rebate-Free Pharmacy Model\nEvernorth announced a new rebate-free pharmacy benefit model designed to help Americans stay healthy and get the medications they need by lowering costs, improving transparency, and supporting local pharmacies so care is always within reach.\n\n**Timeline**: Cigna Healthcare will adopt this model for its fully insured lives beginning in 2027. It will become the standard model available for all Evernorth pharmacy benefits clients beginning in 2028.\n\n**Key Features**:\n- Evernorth will transition toward a new model where discounts negotiated with drug companies are available upfront to Americans buying their medications. This new approach will cut out the complex post-purchase rebate process by making the discounted price of the drug readily available and transparent from the start.\n- For Americans in health plans where they pay the full cost of medications, including millions of people with high-deductible plans, this new model will reduce their monthly cost for a brand-name prescription by an average of 30%.\n\n### Digital Health Initiatives\n- **Clearity by Cigna Healthcare**: A New Tech-Enabled Health Plan Offers Customers Transparent, Predictable Prices\n- **AI-powered tools**: Enhanced customer experience through digital tools\n\n## 5. Growth Strategy\n\nThe company is raising its long-term average annual adjusted EPS growth target to 10%-14% and Our growth strategy consists of our scaled businesses contributing steady, predictable growth and high-growth businesses in attractive markets combined with cross-enterprise leverage to create even greater value.\n\n**Strategic Focus Areas**:\n1. **Evernorth Expansion**: \"Evernorth continues to drive strong results in line with our expectations, primarily driven by our specialty and care services segment\"\n2. **Portfolio Optimization**: The divestment of these assets streamlines The Cigna Group's portfolio and enables it to drive further innovation to support customers.\n3. **Technology Investment**: Planned technology investments in 2026 and 2027 to support the dual-track rebate model.\n4. **Biosimilar Market**: \"By 2030, we expect to see an additional $100 billion of annual specialty drug spend in the United States will be subject to biosimilar competition, and Accredo is well positioned to deliver a differentiated value for our clients, customers and patients\"\n\n## 6. Current and Potential Major Clients\n\n### Existing Major Contracts\n- **Department of Defense**: Its largest PBM contract is with the Department of Defense (current contract through 2029)\n- **Centene**: it recently won a multiyear deal with top-tier insurer Centene.\n- **Prime Therapeutics**: Major contract renewal secured\n- **Department of Energy**: Contract renewal secured\n\n### Client Base Profile\n- Cigna primarily serves employers through self-funding arrangements, and the company operates mostly in the US with 17 million US and 2 million international medical members covered as of December 2024.\n- over 50% of employer clients have been with Cigna for five years or more.\n\n## 7. Financial Data & Performance\n\n### 2024 Results\n- **Revenue**: In 2024, The Cigna Group's revenue was $247.12 billion, an increase of 26.56% compared to the previous year's $195.27 billion.\n- **Net Income**: Earnings were $3.43 billion, a decrease of -33.50%.\n- **Adjusted EPS**: The Cigna Group's adjusted income from operations for 2024 was $7.7 billion, or $27.33 per share, compared with $7.4 billion, or $25.09 per share, for 2023.\n\n### Q4 2024 Highlights\n- Shareholders' net income for fourth quarter 2024 was $1.4 billion, or $5.13 per share\n- Strong performance from Evernorth Health Services\n- Impact from higher stop loss medical costs in Cigna Healthcare\n\n### 2025 Outlook\n- The Cigna Group's outlook for full year 2025 consolidated adjusted income from operations is at least $29.50 per share\n\n### Capital Management\n- In 2024, the Company repurchased 20.9 million shares of common stock for approximately $7.0 billion.\n- the Board of Directors has approved an increase of $6.0 billion in incremental share repurchase authorization, bringing the company's total share repurchase authority to $10.3 billion as of December 31, 2024. On January 30, 2025, the Company's Board of Directors declared a cash quarterly dividend of $1.51 per share\n- This reflects an 8% increase from the 2024 cash quarterly dividend of $1.40 per share.\n\n## 8. Headwinds & Tailwinds\n\n### Headwinds\n1. **Stop Loss Medical Costs**: the stop-loss business faced higher-than-expected medical costs, particularly from high-cost claimants, impacting margins. The overall stop-loss medical care ratio (MCR) ran in the low 90s, which was a mid-single-digit percentage worse than expected.\n2. **PBM Margin Pressure**: executives warned of margin pressures in pharmacy benefit services for 2026-2027, contributing to negative investor sentiment.\n3. **Regulatory Scrutiny**: Increased focus on PBM practices and potential legislative changes\n\n### Tailwinds\n1. **Specialty Pharmacy Growth**: Strong growth in specialty and care services segments\n2. **Biosimilar Opportunities**: the biosimilar use for eligible Humira prescriptions reached nearly 50% by the end of 2024\n3. **Contract Renewals**: Secured major contract renewals, including with Centene and Prime Therapeutics, totaling $90 billion in revenues.\n4. **Market Positioning**: Leadership position in pharmacy benefits management\n\n## 9. Market Shares\n\n### Healthcare Insurance Market\nAccording to multiple industry analyses:\n- Cigna (2%), Cigna (9%) market share in different market segments\n- CIGNA HLTH GRP 41,923,050,893 % 2.50 representing 2.5% market share in accident and health insurance\n- The Cigna Group (Cigna Healthcare) ranks 8th among the largest health insurance companies\n\n### PBM Market Position\n- Express Scripts is one of the three largest PBMs alongside CVS Caremark and Optum Rx\n- Express Scripts' membership has expanded significantly over the past year due in part to the onboarding of Cigna's massive contract win with Centene. In the second quarter, the pharmacy benefit manager boasted 122.5 million members, compared to 98.6 million in the prior-year quarter.\n\n## 10. Comparison to Competitors\n\n### Primary Competitors\nAmong health insurance companies, based on membership, Cigna's biggest competitors are (again) the UnitedHealth Group, Humana, Aetna (part of CVS Health), and Anthem (renamed to Elevance Health in 2022).\n\n### Market Position\n1. **UnitedHealth Group**: UnitedHealth Group {30%), UnitedHealth Group (16%) - Clear market leader\n2. **Elevance Health**: Elevance Health (5%), Elevance Health (12%)\n3. **CVS Health/Aetna**: CVS (Aetna) (12%), CVS (Aetna) (12%)\n4. **Humana**: Humana (19%) in Medicare markets\n\n### Competitive Advantages\n- Its position as a leading provider of specialty pharmacy offerings, which is one of the fastest-growing areas of healthcare, puts it in a unique position of being able to both control and benefit from the rise of that end market.\n- Cigna shines in specific areas like international health insurance and government-sponsored programs. They also boast a strong focus on wellness and disease prevention initiatives.\n\n## 11. Partnerships, Mergers and Acquisitions\n\n### Major Completed Transaction\n**Medicare Business Divestiture (March 2025)**: The Cigna Group today announced the successful completion of the sale of its Medicare Advantage, Cigna Supplemental Benefits, Medicare Part D, and CareAllies businesses to Health Care Service Corporation (HCSC).\n- **Transaction Value**: $3.3 billion acquisition\n- **Impact**: the divestiture, expected to close in Q1 2025, will remove about $12 billion in revenue.\n- **Use of Proceeds**: the majority expected to be allocated to share repurchases.\n\n### Historical M&A Activity\n- **Express Scripts Merger (2018)**: Cigna's acquisition of Express Scripts in the second half of 2018, a deal worth some 67 billion U.S. dollars and one of the health industry's largest deals in that decade.\n\n### Strategic Partnerships\n- Continued pharmacy benefit services agreement with HCSC for divested Medicare businesses\n- Partnership arrangements across healthcare ecosystem\n\n## 12. Recent Developments\n\n### January 2025\n- Board of Directors declared an 8% increase in the quarterly dividend to $1.51 per share and approved an increase of $6.0 billion in incremental share repurchase authorization, bringing total authorization to $10.3 billion\n- Q4 2024 earnings showed revenue growth but earnings pressures from stop-loss costs\n\n### October 2025\n- **Rebate-Free Model Announcement**: Major strategic shift in PBM business model\n- Q3 2025 results showing continued Evernorth strength\n\n### November 2025\n- The Cigna Group named Dr. Amy Flaster Chief Medical Officer effective November 1, 2025, expanding her role to lead clinical strategy across Cigna Healthcare and Evernorth. She will focus on clinical excellence, new care models, clinical team growth, and technology to advance wholeâ€‘person health\n\n### Leadership Changes 2025\n- Brian Evanko has been named President and Chief Operating Officer (COO), The Cigna Group, with responsibility for all business lines reporting to Chairman and CEO David Cordani, effective March 31.\n\n## 13. AI Investment Rating & Fair Value Assessment\n\n### Investment Strengths\n1. **Market Leadership**: Strong position in pharmacy benefits management with Express Scripts\n2. **Growth Strategy**: Clear focus on high-growth Evernorth platform\n3. **Financial Flexibility**: Strong cash generation and capital return program\n4. **Innovation**: Industry-leading rebate-free pharmacy model\n5. **Contract Security**: Long-term contracts with major clients including DoD\n\n### Risk Factors\n1. **Margin Pressure**: Expected 2026-2027 PBM margin compression\n2. **Regulatory Risk**: Increasing scrutiny of PBM practices\n3. **Market Competition**: Intense competition in healthcare insurance\n4. **Execution Risk**: Successful implementation of rebate-free model\n\n### Valuation Assessment\n**Current Price**: $271.00 (as of January 15, 2026)\n**Analyst Targets**: Average $327, Range $270-$378\n**52-Week High**: $350.00\n**P/E Ratio**: 12.31x (relatively attractive)\n\n### Buy Rating: **7.2/10**\n\n### Fair Value Estimate: **$320**\n\n**Investment Thesis**: Cigna represents a solid healthcare services play with strong competitive positioning in pharmacy benefits management. The company's innovative rebate-free model could provide sustainable competitive advantages, though near-term margin pressures create some uncertainty. The attractive valuation (P/E of 12.31x) and strong analyst support (21 buy ratings) suggest good risk-adjusted return potential for growth-oriented investors. The successful Medicare divestiture and capital allocation strategy demonstrate management's focus on value creation. However, regulatory headwinds and margin pressure concerns prevent a higher rating.",
  "generated_date": "2026-01-15T08:25:55.576363",
  "next_refresh_date": "2026-04-16T08:25:55.576363",
  "model": "claude-sonnet-4-20250514",
  "cost": 0.4011543,
  "tokens": {
    "input": 188,
    "output": 5187,
    "cache_creation": 69184,
    "cache_read": 211151
  },
  "tldr_summary": "The Cigna Group is a leading healthcare and insurance services company, operating through Evernorth Health Services and Cigna Healthcare segments, providing pharmacy benefits, medical insurance, and global health solutions to over 182 million customer relationships.\n\nKey investment insights include Cigna's strategic pivot to a revolutionary rebate-free pharmacy model, strong market positioning in pharmacy benefits management via Express Scripts, and continued expansion of high-growth Evernorth services. The company has secured major contracts with the Department of Defense and Centene, demonstrated innovation in biosimilar programs, and recently divested Medicare businesses to streamline operations. Despite facing margin pressures and regulatory scrutiny, Cigna maintains a robust financial position with consistent revenue growth and a commitment to technological innovation and digital health initiatives.\n\nThe AI analysis rates Cigna a Buy at 7.2/10, with a fair value estimate of $320, reflecting attractive valuation and strong long-term growth potential despite near-term market challenges."
}